

ROBO Global®
Healthcare Technology and Innovation ETF
Schedule of Investments
July 31, 2021 (Unaudited)

Description	Shares	Fair Value	Description	Shares	Fair Value
COMMON STOCK – 99.8%			Japan – 0.7%		
Australia – 1.0%			Health Care – 0.7%		
Health Care – 1.0%			Terumo	43,600	\$ 1,683,218
CSL	10,907	\$ 2,316,249	Total Japan		1,683,218
Total Australia		2,316,249	Netherlands – 0.9%		
Belgium – 0.6%			Health Care – 0.9%		
Information Technology – 0.6%			Koninklijke Philips	49,602	2,287,441
Materialise ADR *	66,865	1,455,651	Total Netherlands		2,287,441
Total Belgium		1,455,651	Switzerland – 4.1%		
China – 1.1%			Health Care – 4.1%		
Health Care – 1.1%			Lonza Group	4,391	3,416,676
Ping An Healthcare and Technology * (A)	278,900	2,601,947	Roche Holding	7,324	2,831,252
Total China		2,601,947	Tecan Group	5,942	3,425,681
Denmark – 0.8%			Total Health Care		9,673,609
Health Care – 0.8%			Total Switzerland		9,673,609
GN Store Nord	22,978	2,013,217	United Kingdom – 1.7%		
Total Denmark		2,013,217	Health Care – 1.7%		
France – 2.5%			EMIS Group	99,272	1,780,503
Health Care – 2.5%			Smith & Nephew PLC	107,103	2,177,084
Collectis ADR *	225,462	2,919,733	Total Health Care		3,957,587
Eurofins Scientific	24,778	2,962,865	Total United Kingdom		3,957,587
Total Health Care		5,882,598	United States – 81.8%		
Total France		5,882,598	Health Care – 79.3%		
Germany – 1.5%			1Life Healthcare *	82,898	2,241,562
Health Care – 1.5%			Abbott Laboratories	19,494	2,358,384
Siemens Healthineers (A)	55,203	3,644,808	ABIOMED *	11,320	3,703,225
Total Germany		3,644,808	Agilent Technologies	19,018	2,914,128
Hong Kong – 1.5%			Align Technology *	4,555	3,169,369
Health Care – 1.5%			Alnylam Pharmaceuticals *	11,256	2,014,149
Alibaba Health Information Technology *	1,022,000	1,588,656	Arrowhead Pharmaceuticals *	21,524	1,491,398
JD Health International * (A)	187,100	2,009,149	Avanos Medical *	50,671	1,922,458
Total Health Care		3,597,805	Axogen *	172,718	3,518,266
Total Hong Kong		3,597,805	Baxter International	25,306	1,957,419
Italy – 1.6%			Becton Dickinson	7,489	1,915,312
Health Care – 1.6%			BioMarin Pharmaceutical *	28,619	2,195,936
DiaSorin	18,295	3,712,975	Bio-Rad Laboratories, CI A *	4,849	3,585,884
Total Italy		3,712,975	Boston Scientific *	77,992	3,556,435
			Bristol-Myers Squibb	31,045	2,107,024
			Cardiovascular Systems *	81,695	3,291,492
			CareDx *	38,070	3,199,403
			Catalent *	28,188	3,377,204
			Cerus *	358,461	1,806,643
			Charles River Laboratories International *	9,728	3,958,518
			Codexis *	122,852	2,599,548
			CONMED	15,071	2,078,894
			CryoLife *	95,314	2,573,478
			Danaher	13,187	3,923,000
			DexCom *	8,557	4,411,218
			Editas Medicine, CI A *	97,359	4,075,448
			Edwards Lifesciences *	25,129	2,821,233
			Exact Sciences *	28,231	3,044,431

ROBO Global®
Healthcare Technology and Innovation ETF
Schedule of Investments
July 31, 2021 (Unaudited)

Description	Shares	Fair Value	
Fulgent Genetics *	40,892	\$ 3,772,287	(A) Securities sold within terms of a private placement memorandum, exempt from registration under Section 144A of the Securities Act of 1933, as amended, and may be sold only to dealers in that program or other "accredited investors." These securities have been determined to be liquid under guidelines established by the board of Trustees. As of July 31, 2021, the value of these securities amounted to \$8,255,904, representing 3.5% of the Net Assets of the Fund.
Glaukos *	44,508	2,269,908	
Globus Medical, CI A *	24,001	1,996,163	
Health Catalyst *	57,952	3,364,693	
Hologic *	41,031	3,078,966	
Illumina *	7,839	3,886,184	
Incyte *	36,188	2,799,142	
Insulet *	12,058	3,372,502	
Integra LifeSciences Holdings *	48,520	3,512,363	
Intuitive Surgical *	3,938	3,904,369	
Invitae *	90,990	2,546,810	
IQVIA Holdings *	12,753	3,158,918	
iRhythm Technologies *	50,684	2,590,966	
Masimo *	11,407	3,107,153	
Medpace Holdings *	15,497	2,726,542	
Moderna *	7,950	2,811,120	
NanoString Technologies *	46,706	2,892,970	
Natera *	33,619	3,850,048	
NeoGenomics *	73,736	3,399,230	
Nevro *	18,507	2,868,585	
Novocure *	7,963	1,226,382	
Omniceil *	21,137	3,096,571	
Penumbra *	11,669	3,106,638	
PerkinElmer	19,461	3,546,378	
Quidel *	26,300	3,720,661	
Regeneron Pharmaceuticals *	5,889	3,383,878	
STAAR Surgical *	11,929	1,525,958	
Stryker	9,828	2,662,798	
Tabula Rasa HealthCare *	73,941	3,176,505	
Tactile Systems Technology *	49,819	2,440,135	
Teladoc Health *	11,178	1,659,374	
Thermo Fisher Scientific	7,302	3,943,153	
Veeva Systems, CI A *	5,683	1,890,791	
Veracyte *	99,518	4,434,522	
Vertex Pharmaceuticals *	11,709	2,360,300	
Vocera Communications *	94,180	3,951,792	
		187,846,214	
Information Technology – 2.5%			
3D Systems *	67,204	1,850,798	
Brooks Automation	23,644	2,104,552	
Novanta *	13,533	1,900,169	
		5,855,519	
Total United States		193,701,733	
Total Common Stock (Cost \$222,727,369)		236,528,838	
SHORT-TERM INVESTMENT – 0.2%			
Invesco Government & Agency, CI Institutional, 0.03% (B)	475,887	475,887	
Total Short-Term Investment (Cost \$475,887)		475,887	
Total Investments - 100.0% (Cost \$223,203,256)		\$ 237,004,725	

Percentages based on Net Assets of \$236,945,109.

* Non-income producing security.

(A) Securities sold within terms of a private placement memorandum, exempt from registration under Section 144A of the Securities Act of 1933, as amended, and may be sold only to dealers in that program or other "accredited investors." These securities have been determined to be liquid under guidelines established by the board of Trustees. As of July 31, 2021, the value of these securities amounted to \$8,255,904, representing 3.5% of the Net Assets of the Fund.

(B) Rate shown is the 7-day effective yield as of July 31, 2021.

ADR - American Depository Receipt
CI - Class
PLC - Public Limited Company

As of July 31, 2021, all of the Fund's investments were considered Level 1 of the fair value hierarchy, in accordance with the authoritative guidance under U.S. GAAP.

For the period ended July 31, 2021, there were no transfers in or out of Level 3.

For information regarding the Trust's policy regarding valuation of investments and other significant accounting policies, please refer to the Trust's most recent semi-annual and annual financial statements.

ROB-QH-001-1600